Officer sold
388K → 366K shares held−6% of their stake
Viatris's See Remarks sold $284K of Viatris shares. Nobody planned it ahead of time.
Loading…
Traded Aug 27, 2025 · Filed Mar 10, 2026
A board member of Viatris spent $3K of their very own money to buy Viatris shares. Their pile of Viatris shares grew by 42%.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$2,981
Shares × reported transaction price
<$25K
+41.8%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
20 days after results of Aug 7, 2025, 71 days before results of Nov 6, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Paclitaxel on Aug 19, 2025, 8 days before this trade.
Generic drug approved. Active ingredient: Paclitaxel. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.6% | -2.2% | +0.6% |
| 30 days | -3.6% | +0.5% | -4.0% |
| 90 days | +16.0% | +9.0% | +7.0% |
| 180 days | +18.9% | +13.3% | +5.7% |
Past results only. Not a forecast.
388K → 366K shares held−6% of their stake
Viatris's See Remarks sold $284K of Viatris shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
